ReCode Therapeutics is developing therapeutics for genetically defined diseases with no existing treatment options, including cystic fibrosis and primary ciliary dyskinesia, using their proprietary SORT LNP platform for targeted delivery of genetic medicines
ReCode Therapeutics is developing therapeutics for genetically defined diseases with no existing treatment options, including cystic fibrosis and primary ciliary dyskinesia, using their proprietary SORT LNP platform for targeted delivery of genetic medicines.